MedTrace Logo

Obinutuzumab in Primary FSGS

NCT04983888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

Conditions

  • Primary Focal Segmental Glomerulosclerosis

Interventions

DRUG

Obinutuzumab

1g IV on day one and 1 g IV on day 15, followed by identical course at month 6

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Fernando Fervenza, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2025-06-16
Completion
2025-06-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04983888 on ClinicalTrials.gov